Skip to search formSkip to main contentSkip to account menu

nusinersen

National Institutes of Health

Related topics

Related topics

2 relations
5 ML nusinersen 2.4 MG/ML Injection [Spinraza]

Narrower (1)

Spinraza

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A neuromuscular‐based analysis of the open payments program
In August 2013, the Centers for Medicare and Medicaid Services (CMS) Open Payments Program (OPP) made eligible payment… 
2019
2019
Nucleic Acid Therapeutics for Neurological Diseases
2019
2019
Respiratory assessment in a spinal muscular atrophy infant treated with nusinersen
at younger than 1 year of age in Japan. The present patient had no history of honey intake, or of corn syrup or vegetable juice… 
Review
2019
Review
2019
G176(P) Healthcare utilisation in SMA type 1 patients treated with nusinersen
Background Spinal muscular atrophy (SMA) Type 1 is a neuromuscular disorder that has traditionally resulted in death from… 
Review
2019
Review
2019
Intrathecal nusinersen in older children and adults with spinal muscular atrophy (S5.001)
Objective: To report our experience of treating spinal muscular atrophy (SMA) patients with intrathecal nusinersen who are of 12… 
Review
2018
Review
2018
Putting our best foot forward: Clinical, treatment‐based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy
Spinal muscular atrophy (SMA) is the most common genetic cause of infant mortality. SMA is a spectral disorder and is categorised… 
2018
2018
Ambulatory function and fatigue in nusinersen-treated children with spinal muscular atrophy. (P2.322)
Objective: To examine distance walked and fatigue during the six minute walk test (6MWT) in nusinersen-treated children with… 
2017
2017
C2.4 Historic breakthrough in the treatment of spinal muscular atrophy (5q-sma): nusinersen (spinraza) is the first drug approved for sma
Background Classic proximal 5q-SMA is a progressive motor neuron disorder leading to muscle weakness and atrophy and is the most… 
2017
2017
How the discovery of ISSN 1 led to the first medical therapy for spinal muscular atrophy
Spinal muscular atrophy (SMA), a prominent genetic disease of infant mortality, is caused by low levels of survival motor neuron… 
Review
2017
Review
2017
The SMA Trust: the role of a disease-focused research charity in developing treatments for SMA
SMA is a rare hereditary neuromuscular disease that causes weakness and muscle wasting as a result of the loss of spinal motor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)